Tiffani McDonough
Overview
Explore the profile of Tiffani McDonough including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
374
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Peariso K, Arya R, Glauser T, Abend N, Barcia Aguilar C, Amengual-Gual M, et al.
Neurology
. 2023 Jun;
101(5):e546-e557.
PMID: 37295955
Background And Objectives: The objective of this study was to determine patient-specific factors known proximate to the presentation to emergency care associated with the development of refractory convulsive status epilepticus...
2.
KCND2 variants associated with global developmental delay differentially impair Kv4.2 channel gating
Zhang Y, Tachtsidis G, Schob C, Koko M, Hedrich U, Lerche H, et al.
Hum Mol Genet
. 2021 Jul;
30(23):2300-2314.
PMID: 34245260
Here, we report on six unrelated individuals, all presenting with early-onset global developmental delay, associated with impaired motor, speech and cognitive development, partly with developmental epileptic encephalopathy and physical dysmorphisms....
3.
Sanchez Fernandez I, Abend N, Amengual-Gual M, Anderson A, Arya R, Barcia Aguilar C, et al.
Neurology
. 2020 Jul;
95(9):e1222-e1235.
PMID: 32611646
Objective: To determine whether publication of evidence on delays in time to treatment shortens time to treatment in pediatric refractory convulsive status epilepticus (rSE), we compared time to treatment before...
4.
Basch E, Iasonos A, McDonough T, Barz A, Culkin A, Kris M, et al.
Lancet Oncol
. 2006 Nov;
7(11):903-9.
PMID: 17081915
Background: The Common Terminology Criteria for Adverse Events (CTCAE) are used as standard practice in trials of cancer treatments by clinicians to elicit and report toxic effects. Alternatively, patients could...
5.
Pham D, Kris M, Riely G, Sarkaria I, McDonough T, Chuai S, et al.
J Clin Oncol
. 2006 Mar;
24(11):1700-4.
PMID: 16505411
Purpose: Lung adenocarcinomas with mutations in exons 19 and 21 of the epidermal growth factor receptor gene (EGFR) demonstrate sensitivity to gefitinib or erlotinib. Investigators have reported an association between...